PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
-32.93%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-386.54%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
2.68%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
2.68%
Total costs growth less than half of CRVO's 15.98%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-2.70%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-10.91%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-2.79%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.79%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
1.20%
EPS growth while CRVO declines. John Neff would investigate advantages.
2.99%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
3.80%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
6.10%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.